All ImmixBio News
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective… LOS ANGELES, May 09, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced… The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities presented by current market volatilityImmixBio plans to commence 2 clinical trials in 2022 LOS… Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2… – IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells – ImmixBio anticipates filing an IND for IMX-120 in 2023 – The inflammatory bowel… LOS ANGELES, Feb. 01, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced… January 31, 2022 08:00 ET | Source: Immix Biopharma, Inc. – Manufactured IMX-110 to be utilized in both clinical trials: – 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue… – IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system… – 100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial – IMX-110 is in clinical development as a monotherapy… – IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer – soft tissue sarcoma (STS) mice study – IMX-110 response rate surpassed…ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
Immix Biopharma Announces Share Repurchase Program
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data
IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
